Publication:
Targeting the nucleolus as a therapeutic strategy in human disease.

dc.contributor.authorCorman, Alba
dc.contributor.authorSirozh, Oleksandra
dc.contributor.authorLafarga, Vanesa
dc.contributor.authorFernandez-Capetillo, Oscar
dc.date.accessioned2026-02-27T08:11:04Z
dc.date.available2026-02-27T08:11:04Z
dc.date.issued2023-03
dc.descriptionWe apologize to our colleagues who we failed to cite properly because many relevant primary papers have been replaced by reviews owing to space limitations. We thank Dr Jaime Espinoza for providing relevant input for the manuscript. Work in the laboratory of O.F-C. is funded by grants from the Cancerfonden foundation (21 1529) , the Swedish Research Council (VR, 538-2014-31) , the Spanish Association Against Cancer (AECC, PROYE20101FERN) , and the Spanish Ministry of Science, Innovation and Universities [RTI2018-102204-B-I00 and SAF2017-90900-REDT, cofinanced with European Fundo Europeu de Desenvolvimento Regional (FEDER) funds] .
dc.description.abstractThe nucleolus is the site of ribosome biogenesis, one of the most resource-intensive processes in eukaryotic cells. Accordingly, nucleolar morphology and activity are highly responsive to growth signaling and nucleolar insults which are collectively included in the actively evolving concept of nucleolar stress. Importantly, nucleolar alterations are a prominent feature of multiple human pathologies, including cancer and neurodegeneration, as well as being associated with aging. The past decades have seen numerous attempts to isolate compounds targeting different facets of nucleolar activity. We provide an overview of therapeutic opportunities for targeting nucleoli in different pathologies and currently available therapies.
dc.description.peerreviewed
dc.format.number3
dc.format.page274-287
dc.format.volume48
dc.identifier.citationTrends Biochem Sci . 2023 Mar;48(3):274-287.
dc.identifier.journalTrends Biochem Sci
dc.identifier.pubmedID36229381
dc.identifier.urihttps://hdl.handle.net/20.500.12105/27277
dc.language.isoeng
dc.publisherCell Press
dc.relation.publisherversionhttp:// doi: 10.1016/j.tibs.2022.09.006.
dc.repisalud.institucionCNIO
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Inestabilidad Genómica
dc.rights.accessRightsopen access
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectRNA Pol I
dc.subjectaging
dc.subjectcancer
dc.subjectdrug development
dc.subjectribosome biogenesis, nucleolar stress
dc.titleTargeting the nucleolus as a therapeutic strategy in human disease.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublicationeb478d8c-dd11-4b47-8795-7ac57cb60b2d
relation.isAuthorOfPublication.latestForDiscoveryeb478d8c-dd11-4b47-8795-7ac57cb60b2d

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
targetingthenucleouls_2022.pdf
Size:
2.97 MB
Format:
Adobe Portable Document Format